Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy‐Based Cross‐Sectional Survey
Authors' conclusion
Many SEMA-WM users remained on 1 mg and reported weight loss and medication reductions similar to the overall cohort. Findings indicate that some users appear to obtain the desired effect at 1 mg
Study context
- Population
- Adults redeeming a semaglutide for weight management (SEMA-WM) prescription at 28 Danish community pharmacies, March–May 2025of 1470 invited
- Participants
- 767 adults
- Outcome
- SEMA-WM treatment patterns
Methodological detailsquestionnaire-based survey, community pharmacy-based, 28 Danish community pharmacies, 6-month follow-up survey of first-time users
- Questionnaire-based survey
- Community pharmacy-based
- 28 Danish community pharmacies
- 6-month follow-up survey of first-time users
Main finding
As reported in the abstract
Used 1 mg as current dose
45%
Expected to reach 2.4 mg
8%
Dosed by "counting clicks" on the injection pen, in contrast with official prescribing guidelines
10%
Observational data: associations, not effects.
Further findings
Self-reported weight loss by treatment duration
Self-reported weight loss by treatment duration
- Weight loss by treatment duration was similar among 1 mg users
Reduced/discontinued concomitant medication use after SEMA-WM initiation
- Any concomitant medication
- 24%
- Muscle/joint pain medication
- 30%
- Antihypertensives
- 24%
- Reduced/discontinued medication use was similar among 1 mg users
Persistence among first-time users · 6 months
- Still using SEMA-WM (n = 42 first-time users)
- 83%
- Using 1 mg
- 60%
- Discontinued treatment
- 17%
Safety
Reason for discontinuation · 6 months
- Side effects were the most reported reason among users who discontinued (17%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →